Tyme Technologies, Inc.
(NASDAQ : TYME)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.95%42.960.9%$1172.19m
LLYEli Lilly and Company
1.04%124.001.0%$1160.63m
JNJJohnson & Johnson
0.86%136.590.6%$960.96m
MRKMerck & Co., Inc.
1.12%80.720.6%$933.10m
BMYBristol-Myers Squibb Company
1.70%50.981.4%$779.97m
ABBVAbbVie, Inc.
1.60%80.012.2%$667.49m
AZNAstraZeneca PLC Sponsored ADR
1.27%40.951.3%$191.16m
NVSNovartis AG Sponsored ADR
0.30%90.780.2%$183.03m
GSKGlaxoSmithKline plc Sponsored ADR
0.03%40.550.2%$135.60m
NVONovo Nordisk A/S Sponsored ADR Class B
0.28%49.800.1%$67.28m
SNYSanofi Sponsored ADR
-0.36%41.180.2%$36.78m
LCILannett Company, Inc.
0.64%9.4136.7%$16.84m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.70%1.801.7%$0.06m
EPIXESSA Pharma Inc
1.96%3.640.1%$0.04m

Company Profile

Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine derivatives and has shown complete or partial imaging responses in 15 different cancer subtypes, including solid tumors, sarcomas, gliomas and hematological malignancies, without demonstrating drug-related severe adverse events. The company was founded on November 22, 2011 and is headquartered in New York, NY.